posted on 2022-09-06, 05:29authored byGeqing WangGeqing Wang, B Mohanty, ML Williams, BC Doak, R Dhouib, M Totsika, RM McMahon, G Sharma, D Zheng, MR Bentley, Y Ka-Yan Chin, J Horne, DK Chalmers, Begona HerasBegona Heras, MJ Scanlon
DsbA enzymes catalyze oxidative folding of proteins that are secreted into the periplasm of Gram-negative bacteria, and they are indispensable for the virulence of human pathogens such as Vibrio cholerae and Escherichia coli. Therefore, targeting DsbA represents an attractive approach to control bacterial virulence. X-ray crystal structures reveal that DsbA enzymes share a similar fold, however, the hydrophobic groove adjacent to the active site, which is implicated in substrate binding, is shorter and flatter in the structure of V. cholerae DsbA (VcDsbA) compared to E. coli DsbA (EcDsbA). The flat and largely featureless nature of this hydrophobic groove is challenging for the development of small molecule inhibitors. Using fragment-based screening approaches, we have identified a novel small molecule, based on the benzimidazole scaffold, that binds to the hydrophobic groove of oxidized VcDsbA with a KD of 446±10 μM. The same benzimidazole compound has ∼8-fold selectivity for VcDsbA over EcDsbA and binds to oxidized EcDsbA, with KD>3.5 mM. We generated a model of the benzimidazole complex with VcDsbA using NMR data but were unable to determine the structure of the benzimidazole bound EcDsbA using either NMR or X-ray crystallography. Therefore, a structural basis for the observed selectivity is unclear. To better understand ligand binding to these two enzymes we crystallized each of them in complex with a known ligand, the bile salt sodium taurocholate. The crystal structures show that taurocholate adopts different binding poses in complex with VcDsbA and EcDsbA, and reveal the protein-ligand interactions that stabilize the different modes of binding. This work highlights the capacity of fragment-based drug discovery to identify inhibitors of challenging protein targets. In addition, it provides a starting point for development of more potent and specific VcDsbA inhibitors that act through a novel anti-virulence mechanism.
Funding
This work was supported by the National Health and Medical Research Council (NHMRC) (Project Grants 1099151 & 1144046) and the Australian Research Council (ARC) (Industry Transformation Training Centre Grant IC180100021). Dr.Begona Heras was supported by an ARC Future Fellowship (FT130100580). Martin Williams was the recipient of an Australian Postgraduate Award. We would like to acknowledge the La Trobe University-Comprehensive Proteomics Platform and the Monash Fragment Platform (MFP) for providing infrastructure and expertise. This research was undertaken using the MX1, MX2 beamlines at the Australian Synchrotron, part of ANSTO. Some of the NMR data were acquired at the NMR Facility of Bio21. Open access publishing facilitated by Monash University, as part of the Wiley - Monash University agreement via the Council of Australian University Librarians.